Dilemmas in the management of atrial fibrillation in chronic kidney disease

Journal of the American Society of Nephrology

Volumn 20, Issue 4, 2009, Pages 705-711

  Reinecke, Holger ^a,d   Brand, Eva ^a   Mesters, Rolf ^a   Schäbitz, Wolf R̈diger ^b   Fisher, Marc ^c   Pavenstädt, Hermann ^a   Breithardt, G̈nter ^a  

^a Department of Cardiology and Angiology ^*  (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d Klinik und Poliklinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; DALTEPARIN; DANAPAROID; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN; WARFARIN;

ALGORITHM; ANTICOAGULATION; BLEEDING; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM;

EID: 65249183151     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2007111207     Document Type: Review

References (48)

1. US Renal Data System: USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006
2. Hamer RA, El Nahas AM: The burden of chronic kidney disease. BMJ 332: 563-564, 2006
3. Barsoum RS: Chronic kidney disease in the developing world. N Engl J Med 354: 997999, 2006
4. Brosius FC 3rd, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA, Pen- nathur S, Smith GL, Wilson PW: Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: A science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: Developed in collaboration with the National Kidney Foundation. Circulation 114: 1083-1087, 2006
5. Levey AS, Andreoli SP, DuBose T, Prov- enzano R, Collins AJ: Chronic kidney disease: Common, harmful, and treatable- World Kidney Day 2007. J Am Soc Nephrol 18: 374-378, 2007
6. Eddy AA, Neilson EG: Chronic kidney disease progression. J Am Soc Nephrol 17: 2964-2966, 2006
7. Meguid El Nahas A, Bello AK: Chronic kidney disease: The global challenge. Lancet 365: 331-340, 2005
8. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 139: 137-147, 2003
9. Frei U, Schober-Halstenberg HJ: Annual report of renal replacement therapies in Germany. QuaSi-Niere Jahresbericht 2005/ 2006. Available at www.quasi-niere.de. Accessed October 27, 2008
10. Parfrey PS, Foley RN: The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 10: 1606-1615, 1999
11. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospi- talization. N Engl J Med 351: 1296-1305, 2004
12. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, Knudtson ML: The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 44: 1587-1592, 2004
13. Reinecke H, Trey T, Matzkies F, Fobker M, Breithardt G, Schaefer RM: Grade ofchronic renal failure, and acute and long-term outcome after percutaneous coronary interventions. Kidney Int 63: 696-701, 2003
14. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA: Relation between renal dysfunction and cardiovascular outcomes after myo- cardial infarction. N Engl J Med 351:1285-1295, 2004
15. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamo- rano JL: ACC/AHA/ESC 2006 guidelines for the management ofpatients with atrial fibrillation: Executive summary-A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 48: 854-906, 2006
16. US Renal Data System: USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005
17. Vazquez E, Sanchez-Perales C, Borrego F, Garcia-Cortes MJ, Lozano C, Guzman M, Gil JM, Borrego MJ, Perez V: Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 140: 886-890, 2000
18. Bozbas H, Atar I, Yildirir A, Ozgul A, Uyar M, Ozdemir N, Muderrisoglu H, Ozin B: Prevalence and predictors of arrhythmia in end stage renal disease patients on hemodialysis. Ren Fail 29: 331-339, 2007
19. Genovesi S, Pogliani D, Faini A, Valsecchi MG, Riva A, Stefani F, Acquistapace I, Stella A, Bonforte G, DeVecchi A, DeCristofaro V, Buccianti G, Vincenti A: Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 46: 897-902, 2005
20. Atar I, Konas D, Acikel S, Kulah E, Atar A, ozbas H, Gulmez O, Sezer S, Yildirir A, Ozdemir N, Muderrisoglu H, Ozin B: Frequency of atrial fibrillation and factors related to its development in dialysis patients. Int J Cardiol 106: 47-51, 2006
21. Abbott KC, Trespalacios FC, Taylor AJ, Ag- odoa LY: Atrial fibrillation in chronic dialysis patients in the United States: Risk factors for hospitalization and mortality. BMC Nephrol 4: 1-10, 2003
22. K/DOQI Workgroup: K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45[Suppl 3]: S1-S153, 2005
23. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM: Renin-angiotensin system and cardiovascular risk. Lancet 369: 1208-1219, 2007
24. Hausberg M, Grassi G: Mechanisms of sympathetic overactivity in patients with chronic renal failure: A role for chemoreflex activation? J Hypertens 25: 47-49, 2007
25. Vazquez E, Sanchez-Perales C, Lozano C, Garcia-Cortes MJ, Borrego F, Guzman M, Perez P, Pagola C, Borrego MJ, Perez V: Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol 92: 868-871, 2003
26. Nakayama M, Metoki H, Terawaki H, Oh- kubo T, Kikuya M, Sato T, Nakayama K, Asayama K, Inoue R, Hashimoto J, Totsune K, Hoshi H, Ito S, Imai Y: Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population-the Ohasama study. Nephrol Dial Transplant 22: 1910-1915, 2007
27. Falgá C, Capdevila JA, Soler S, Rabuñal R, Sánchez Muiñoz-Torrero JF, Gallego P, Mon- real M: Clinical outcome of patients with venous thromboembolism and renal insufficiency: Findings from the RIETE registry. Thromb Haemost 98: 771-776, 2007
28. Vazquez E, Sanchez-Perales C, Garcia- Cortes MJ, Borrego F, Lozano C, Guzman M, Gil JM, Liebana A, Perez P, Borrego MJ, Perez V: Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants? Int J Cardiol 87: 135-139, 2003
29. Wiesholzer M, Harm F, Tomasec G, BarbieriG, Putz D, Balcke P: Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol 21: 35-39, 2001
30. Lo DS, Rabbat CG, Clase CM: Thromboembolism and anticoagulant management in hemodialysis patients: A practical guide to clinical management. Thromb Res 118: 385-395, 2006
31. Farooq V, Hegarty J, Chandrasekar T, Lamerton EH, Mitra S, Houghton JB, Kalra PA, Waldek S, O'Donoghue DJ, Wood GN: Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis 43: 531-537, 2004
32. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin. Chest 126: 188S-203S, 2004
33. George-Phillips KL, Bungard TJ: Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction. Pharmacotherapy 26: 1479-1490, 2006
34. Lim W, Dentali F, Eikelboom JW, Crowther MA: Meta-analysis: Low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144: 673-684, 2006
35. Stobe J, Siegemund A, Achenbach H, Preiss C, Preiss R: Evaluation of the pharmacoki- netics of dalteparin in patients with renal insufficiency. Int J Clin Pharmacol Ther 44: 455-465, 2006
36. Tincani E, Mannucci C, Casolari B, Turrini F, Crowther MA, Prisco D, Cenci AM, Bondi M: Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica 91: 976-979, 2006
37. Kaw D, Malhotra D: Platelet dysfunction and end-stage renal disease. Semin Dial 19: 317-322, 2006
38. Boccardo P, Remuzzi G, Galbusera M: Platelet dysfunction in renal failure. Semin Thromb Haemost 30: 579-589, 2004
39. Tveit DP, Hypolite IO, Hshieh P, Cruess D, Agodoa LY, Welch PG, Abbott KC: Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis 39: 1011-1017, 2002
40. Iseki K, Kinjo K, Kimura Y, Osawa A, Fukiyama K: Evidence for high risk of cerebral haemorrhage in chronic dialysis patients. Kidney Int 44: 1086-1090, 1993
41. Gangji AS, Sohal AS, Treleaven D, Crowther MA: Bleeding in patients with renal insufficiency: A practical guide to clinical management. Thromb Res 118: 423-428, 2006
42. Hylek EM, Skates SJ, Sheehan MA, Singer DE: An analysis ofthe lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335: 540-546, 1996
43. Gage BF, Waterman AD, Shannon W, Bo-echler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 285: 2864-2870, 2001
44. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolera- bility of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115: 2689-2696, 2007
45. Dahri K, Loewen P: The risk of bleeding with warfarin: A systematic review and performance analysis of clinical prediction rules. Thromb Haemost 98: 980-987, 2007
46. Wyse G: Bleeding while starting anticoagula- tion for thromboembolism prophylaxis in elderly patients with atrial fibrillation: From bad to worse. Circulation 115: 2684-2686, 2007
47. Linkins LA, Choi PT, Douketis JD: Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thrombo- embolism: A meta-analysis. Ann Intern Med 139: 893-900, 2003
48. Ritz E: Minor renal dysfunction: An emerging independent cardiovascular risk factor. Heart 89: 963-964, 2003